Changchun High-tech: Subsidiary Kamelitropine Lin Clinical Trial Application Approved, currently no similar products on the market in China.

Changchun High-tech announced that its holding subsidiary Jin Sai Pharmaceutical received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The domestic production drug registration clinical trial application of Jin Sai Pharmaceutical's Cabergoline Tablets has been approved. Cabergoline Tablets are a dopamine receptor agonist developed by Jin Sai Pharmaceutical, intended for the treatment of hyperprolactinemia/pituitary prolactinomas. Currently, there are no similar products on the market in China. The approval of this clinical trial application can promote the subsequent clinical development of this product and meet the unmet clinical needs of patients.